Projects

Ing. Martina Poturnajová, PhD.
independent researcher

International

Current
  • International networking on in vitro colon models simulating gut microbiota mediated interactions
    Program: COST
    Duration: 9. 10. 2024 – 8. 10. 2028
Finished
  • Identification of lncRNA Biomarkers for Metastatic Potential in Colorectal Cancer through RNA Expression Profiling
    Program: Other
    Duration: 1. 11. 2024 – 31. 10. 2025
  • A4L_ACTIONS POst-Transcriptional Oncogenic Modifications And their Consequences
    Program: Other
    Duration: 1. 3. 2023 – 29. 2. 2024
  • A4L_ACTIONS Characterisation of CRC patient- derived xenolines and its ALDH1A1 knockouts.
    Program: Other
    Duration: 1. 11. 2022 – 31. 10. 2023
  • Targeted combination therapy of colon cancer with therapeutic gene/drug loaded novel dendritic nanocarriers
    Program: Bilateral - other
    Duration: 3. 9. 2018 – 30. 11. 2022
  • Innovative Nanopharmaceuticals: Targeting Breast Cancer Stem Cells by a Novel Combination of Epigenetic and Anticancer Drugs with Gene Therapy
    Program: ERANET
    Duration: 1. 1. 2017 – 30. 6. 2021

National

Current
  • Carbonic anhydrase I and cancer cell tumorigenicity
    Program: VEGA
    Duration: 1. 1. 2025 – 31. 12. 2028
  • Identification of novel biomarkers linked to the relapse of metastatic colorectal cancer after metastasectomy
    Program: SRDA
    Duration: 1. 7. 2022 – 30. 6. 2026
  • Verification of clinically relevant biomarkers for the stratification of CRC patients by molecular and bioinformatic methods.
    Program: VEGA
    Duration: 1. 1. 2022 – 31. 12. 2025
Finished
  • The role of mitochondria in progression of colorectal cancer
    Program: VEGA
    Duration: 1. 1. 2021 – 31. 12. 2024
  • Markers overlapping chemoresistance and metastatic potential in colorectal cancer - aldehyde dehydrogenase and its clinical relevance
    Program: Other projects
    Duration: 1. 11. 2019 – 31. 12. 2022
  • TArgetiNg Dna mEthylation by epigenetic editing and its implementation into personalised diagnostics and therapy of uveal Melanoma
    Program: SRDA
    Duration: 1. 8. 2018 – 31. 12. 2022
  • Mechanism of the mesenchymal stromal cell-induced tolerance to antitumor treatment and targeted therapeutic intervention in the breast cancer cells
    Program: SRDA
    Duration: 1. 7. 2017 – 31. 12. 2021
  • Cellular and molecular traits of human metastasis-initiating cells at different stages of metastasis development.
    Program: VEGA
    Duration: 1. 1. 2017 – 31. 12. 2020
  • The role of ALDH1 in chemoresistance of cancer cells
    Program: VEGA
    Duration: 1. 1. 2017 – 31. 12. 2020
  • The role of CA IX in adaptation to tumor microenvironment and in resistance to anticancer therapy: molecular mechanisms and clinical implications
    Program: SRDA
    Duration: 1. 7. 2016 – 31. 12. 2020
  • Targeted Augmented Cellular Therapy against Tumor Initiating and Chemoresistant Cells
    Program: SRDA
    Duration: 1. 7. 2012 – 31. 12. 2015
  • Molecular mechanisms of tumor-driven mesenchymal stromal cells‘ differentiation
    Program: VEGA
    Duration: 1. 1. 2011 – 31. 12. 2014
  • Identification of alternative protein partners of tumor suppressors from INK4 family
    Program: VEGA
    Duration: 1. 1. 2009 – 31. 12. 2011
  • Human mesenchymal stem cells as cytoreagents for metastasis-targeted therapy
    Program: SRDA
    Duration: 1. 6. 2008 – 30. 6. 2011
  • Biological effect of novel RET gene mutation connected to multiple endocrine neoplasia type 2
    Program: VEGA
    Duration: 1. 1. 2008 – 31. 12. 2010
  • Implementation of histology and molecular-biology methods in the tumor heterogenity analysis
    Program: Intra-constitutional
    Duration: 1. 1. 2010 – 31. 12. 2010
  • Mutations of ret proto-oncogene connected with thyroid carcinomas
    Program: VEGA
    Duration: 1. 1. 2005 – 1. 12. 2007
Employees